Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 1082-1091

  Sun, Wenyue ^a   Zaboli, David ^a   Wang, Hao ^a   Liu, Yan ^a   Arnaoutakis, Demetri ^a   Khan, Tanbir ^a   Khan, Zubair ^a   Koch, Wayne M ^a   Califano, Joseph A ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A1; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P16; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ACTB GENE; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CCNA1 GENE; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DAPK GENE; DCC GENE; DNA METHYLATION; FEMALE; GENETIC ANALYSIS; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MINT31 GENE; MULTIVARIATE ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; P16 GENE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SALIVA ANALYSIS; SQUAMOUS CELL CARCINOMA; TIMP3 GENE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARCINOMA, SQUAMOUS CELL; CYCLIN A1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENES, DCC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; SALIVA; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR SUPPRESSOR PROTEINS;

EID: 84863116388     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2392     Document Type: Article

References (47)

1. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-54.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
3. Mydlarz WK, Hennessey PT, Califano JA. Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opin Med Diagn 2010;4:53-65.
4. Yao M, Epstein JB, Modi BJ, Pytynia KB, Mundt AJ, Feldman LE. Current surgical treatment of squamous cell carcinoma of the head and neck. Oral Oncol 2007;43:213-23. (Pubitemid 46228018)
5. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994;73: 187-90. (Pubitemid 24012742)
6. Poeta ML, Manola J, Goldenberg D, Forastiere A, Califano JA, Ridge JA, et al. The ligamp TP53 assay for detection of minimal residual disease in head and neck squamous cell carcinoma surgical margins. Clin Cancer Res 2009;15:7658-65.
7. van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel MW, et al. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 2004;10:3614-20. (Pubitemid 38697594)
8. Clark SJ, Melki J. DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 2002;21:5380-7. (Pubitemid 34983474)
9. Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006;7:77-82. (Pubitemid 43025396)
10. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54. (Pubitemid 37448928)
11. Baur AS, Shaw P, Burri N, Delacretaz F, Bosman FT, Chaubert P. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 1999;94:1773-81. (Pubitemid 29411328)
12. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989;83:155-8.
13. Little M, Wainwright B. Methylation and p16: suppressing the suppressor. Nat Med 1995;1:633-4.
14. Esteller M. Cancer epigenetics:DNAmethylation and chromatin alterations in human cancer. Adv Exp Med Biol 2003;532:39-49. (Pubitemid 37176778)
15. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998;17:2413-7. (Pubitemid 28515395)
16. Sato M, Mori Y, Sakurada A, Fujimura S, Horii A. The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet 1998;103:96-101. (Pubitemid 28398393)
17. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A 1995;92: 7416-9.
18. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-9. (Pubitemid 30437320)
19. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 2000;60:6236-42.
20. Cirincione R, Lintas C, Conte D, Mariani L, Roz L, Vignola AM, et al. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int J Cancer 2006;118:1248-53. (Pubitemid 43185613)
21. Bernard PS, Wittwer CT. Real-time PCR technology for cancer diagnostics. Clin Chem 2002;48:1178-85. (Pubitemid 34809822)
22. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
23. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001;93:1747-52. (Pubitemid 33130264)
24. El-Naggar AK, Mao L, Staerkel G, Coombes MM, Tucker SL, Luna MA, et al. Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn 2001;3:164-70. (Pubitemid 33100337)
25. Nunes DN, Kowalski LP, Simpson AJ. Detection of oral and oropharyngeal cancer by microsatellite analysis in mouth washes and lesion brushings. Oral Oncol 2000;36:525-8.
26. Rosas SL, Koch W, daCosta Carvalho MG, WuL, Califano J, Westra W, et al. Promoter hypermethylation patterns of p16, O6-methylguanine- DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001; 61:939-42. (Pubitemid 32174408)
27. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 2008;14:97-107. (Pubitemid 351377983)
28. Carvalho AL, Henrique R, Jeronimo C, Nayak C, Reddy A, Hoque MO, et al. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res 2011;17:4782-9.
29. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6. (Pubitemid 26296693)
30. Pattani KM, Zhang Z, Demokan S, Glazer C, Loyo M, Goodman S, et al. Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila). 2010;3: 1093-103.
31. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003;9:1370-5. (Pubitemid 36418388)
32. Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, Carvalho AL, et al. An epigenetic marker panel for detection of lung cancer using cellfree serum DNA. Clin Cancer Res 2011;17:4494-503.
33. Nayak CS, Carvalho AL, Jeronimo C, Henrique R, Kim MM, Hoque MO, et al. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. Laryngoscope 2007;117:1376-80. (Pubitemid 47356838)
34. Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, Xiao Y, et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 2004;64:5982-7. (Pubitemid 39129394)
35. Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, Poeta L, et al. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res 2006;66:9401-7. (Pubitemid 44623636)
36. Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi M, Sonoda T, et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 2002;8: 3164-71. (Pubitemid 35155026)
37. Zhao M, Rosenbaum E, Carvalho AL, Koch W, Jiang W, Sidransky D, et al. Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer 2005;117: 605-10. (Pubitemid 41504548)
38. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
39. Chang IM, Gelman R, Pagano M. Corrected group prognostic curves and summary statistics. J Chronic Dis 1982;35:669-74. (Pubitemid 12099867)
40. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999;59:798-802. (Pubitemid 29086729)
41. Brueckl WM, Grombach J, Wein A, Ruckert S, Porzner M, Dietmaier W, et al. Alterations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) are found frequently in human colorectal tumours displaying either microsatellite stability (MSS) or instability (MSI). Cancer Lett 2005;223: 137-42. (Pubitemid 40693718)
42. Yokoyama T, Nakamura H, Otani Y, Kubota T, Fujimoto N, Seiki M, et al. Differences between scirrhous and non-scirrhous human gastric carcinomas from the aspect of proMMP-2 activation regulated by TIMP-3. Clin Exp Metastasis 2004;21:223-33. (Pubitemid 39158499)
43. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in nonsmall cell lung cancers. Cancer Res 2001;61:249-55. (Pubitemid 32095725)
44. De Schutter H, Geeraerts H, Verbeken E, Nuyts S. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. Oncol Rep 2009;21:507-13.
45. Ninomiya I, Kawakami K, Fushida S, Fujimura T, Funaki H, Takamura H, et al. Quantitative detection of TIMP-3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep 2008;20:1489-95.
46. Righini CA, de Fraipont F, Timsit JF, Faure C, Brambilla E, Reyt E, et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res 2007;13:1179-85. (Pubitemid 46424058)
47. Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 2009;69:5269-84.